Valeant Pharma (VRX) Affirms Being in Discussions for Various Divestitures; May Include Salix Sale

November 1, 2016 5:37 PM EDT

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Valeant Pharma (NYSE: VRX) issued the following statement regarding comments attributed to anonymous sources in a press report regarding its Gastroenterology business unit:

"In accordance with its duties to shareholders and other stakeholders, management evaluates any transaction relating to core or non-core business units in accordance with the best interest of its shareholders and stakeholders. We are currently in discussions with third parties for various divestitures including but not limited to Salix. The discussions may or may not lead to a definitive agreement. Valeant does not intend to comment further on market speculation or disclose any developments unless and until it otherwise deems further disclosure is appropriate or required."



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Hot Corp. News, Hot M&A, Mergers and Acquisitions, Rumors, Spinoffs

Add Your Comment